Meeting
2013 ASCO Annual Meeting
Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.
Authors
Reinhard Dummer
University Hospital Zurich, Zurich, Switzerland
Reinhard Dummer , Caroline Robert , Marta Nyakas , Grant A. McArthur , Ragini Reiney Kudchadkar , Carlos Gomez-Roca , Ryan J. Sullivan , Keith Flaherty , Carla Murer , Daniela Michel , Zhongwen Tang , Laure A. De Parseval , Jean-Pierre Delord
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01436656
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9028)
DOI
10.1200/jco.2013.31.15_suppl.9028
Abstract #
9028
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).
First Author: Alain Patrick Algazi
Poster
2014 ASCO Annual Meeting
A phase I trial of BKM120 combined with vemurafenib in BRAFV600E/k mutant advanced melanoma.
First Author: Alain Patrick Algazi
Poster
2021 ASCO Annual Meeting
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.
First Author: Lisa Zimmer
Poster
2021 ASCO Annual Meeting
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.
First Author: Vivek Subbiah